DFM Funding Monitor

Targeting Cancer with ERV Vaccinesbroad

CancERVacc · Horizon Europe grant · 2022-07-01–2025-10-31

EC contribution

€2,500,000

Total cost

€12,179,813

Beneficiaries

1

About the data

Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2021-ACCELERATOROPEN-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2021-ACCELERATOROPEN-01. CORDIS record →

Objective

InProTher (IPT) is developing a unique immunotherapy BreakImmune that effectively targets endogenous retroviruses (HERVs) to treat cancer. HERVs are not expressed in normal tissues, but are expressed in several major cancers, such as breast (88%), prostate (90%), ovarian (90%), and pancreatic (80%). Thus, HERVs can be a potential target for the immune system to destroy tumor cells. IPT technology relies on the engineering of HERVK antigens to be used as effective cancer vaccines. The administration of BreakImmune, the mutated HERVK in Ad19/MVA viral vectors, induces both strong antibody and T-cell immune responses able to destroy cancer cells in multiple cancer types. Our first product is IPT001, a first in class vaccine against solid cancers in combination with checkpoint inhibitors.

Beneficiaries (1)

Organisation	Country	Role	EC contribution	SME
INPROTHER APS	DK	coordinator	€2,500,000	Yes

Get the DFM funding briefing — free

New EU defence calls, tenders and awards in your inbox.

Countries

Germany France Poland Spain Italy

Sectors

Security equipment Military vehicles Weapons & ammunition Military aircraft Warships & naval Military electronics

Sources

calls tenders awards research

I agree to receive the DFM Analysis briefing and funding alerts by email. I can unsubscribe at any time.

Website

Subscribe free

We store your email only to send the DFM briefing/alerts and to add you to DFM Analysis. Unsubscribe anytime.

Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.